Kanagawa Cancer Center

Kanagawa, Yokohama 241-8515

3 studies enrolling now · 7 studies all time

What they study most

Biliary Tract Cancer, Bladder Cancer, Colorectal Cancer, Esophageal Adenocarcinoma, Extrapulmonary Neuroendocrine Cancer (epNEC), Gastroesophageal Junction Adenocarcinoma, Lung Cancer, Non-squamous, Non-small Cell, Lung Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Neoplasms, Non-small Cell Lung Cancer

Studies at this site

• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread — Recruiting now
• DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations — Recruiting now
• A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer — Running, not enrolling
• A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine — Running, not enrolling
• Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment — Running, not enrolling
• Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder — Completed